Lazarus Medical Technologies, LLC (LMT) has completed development of a propriety, leading edge, chest drainage system called the Repositionable Chest Tube™(RCT). The Technology is highly differentiated relative to current commercially available products and the company expects it to minimize surgical procedures as it shows superiority in removing unwanted fluid from the chest cavity in terms of efficiency and speed relative to current devices. Today’s chest drainage systems are stationary. LMT’s RCT™ is the first repositionable chest drainage system. The current products date from 1875. The original chest tubes in the 19th century were rubber, now they are thermoplastics. In the U.S. we are addressing initially 600,000 patients of the 2.4 million which use chest drainage. This market represents an estimated market opportunity of $216 million per year. Animal testing was completed at the University of Utah. The RCT™ is legal to see under FDA regulations. We have a sterile product which is available for sale. We are looking for the RCT™ to decrease hospital stay by more than 5 days. More efficient removal of infected fluid in the pneumonia cases should decrease the 17,000 annual deaths in this group. Decreasing the hospital stay three days, per patient would save U.S. hospitals in excess of $1 billion annually. We have five patents pending and one issued. LMT is seeking outside funding in the amount of $2.2 Million to support expanding our product line and establish national sales and distribution channels.